Dr Melvin Heng, group CEO of Thomson Medical, has been appointed acting group CEO of the company's separately listed subsidiary TMC Life Sciences.
Heng is now a non-executive, non-independent director of TMC, which is listed in Malaysia.
This move follows the suspension of TMC's group CEO Wan Nadiah Binti Wan Mohd Abdullah Yaakob with effect from Jan 29 until further notice.
No reasons were given.
TMC's board says with Heng assuming the group CEO role temporarily, it is business as usual.
"The company shall announce further developments on the above matter as and when necessary," says TMC.
See also: Sembcorp issues $350 mil of guaranteed notes due 2036 at 3.65%
According to Wan Nadiah's profile on TMC's website, she joined the company in 2017 and was COO of clinical services at Sunway Medical Centre.
Prior to Sunway, she was an associate consultant with the Boston Consulting Group.
Thomson Medical shares closed Jan 29 at 5.4 cents, down 1.82%.
TMC Life Sciences, on the other hand, closed the day at RM0.73, up 1.39%.
